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ABSTRACT
Background: Given the modest responses to everolimus, a mTOR inhibitor, in 
multiple tumor types, there is a pressing need to identify predictive biomarkers 
for this drug. Using targeted ultra-deep sequencing, we aimed to explore genomic 
alterations that confer extreme sensitivity to everolimus.
Results: We collected formalin-fixed paraffin-embedded tumor/normal pairs from 
39 patients (22 with exceptional clinical benefit, 17 with no clinical benefit) who were 
treated with everolimus across various tumor types (13 gastric cancers, 15 renal 
cell carcinomas, 2 thyroid cancers, 2 head and neck cancer, and 7 sarcomas). Ion 
AmpliSeqTM Comprehensive Cancer Panel was used to identify alterations across all 
exons of 409 target genes. Tumors were sequenced to a median coverage of 552x. 
Cancer genomes are characterized by 219 somatic single-nucleotide variants (181 
missense, 9 nonsense, 7 splice-site) and 22 frameshift insertions/deletions, with 
a median of 2.1 mutations per Mb (0 to 12.4 mutations per Mb). Overall, genomic 
alterations with activating effect on mTOR signaling were identified in 10 of 22 (45%) 
patients with clinical benefit and these include MTOR, TSC1, TSC2, NF1, PIK3CA and 
PIK3CG mutations. Recurrently mutated genes in chromatin remodeling genes (BAP1; 
n = 2, 12%) and receptor tyrosine kinase signaling (FGFR4; n = 2, 12%) were noted 
only in patients without clinical benefit.
Conclusions: Regardless of different cancer types, mTOR-pathway-activating 
mutations confer sensitivity to everolimus. Targeted sequencing of mTOR pathway 
genes facilitates identification of potential candidates for mTOR inhibitors.
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BACKGROUND
Mammalian target of rapamycin (mTOR) is a key 
component of phosphatidylinositol 3-kinase (PI3K) 
pathway that plays an important role of cell growth and 
proliferation, metabolism, and angiogenesis [1]. Since 
inhibition of mTOR signaling can abrogate the cellular 
response to growth factor receptor activation, targeting 
mTOR activation is an attractive approach for cancer 
therapy. 
Everolimus is a rapamycin analog that is being 
developed as an inhibitor of mTORC1. Like rapamycin, 
everolimus binds the cyclophilin FKBP-12, and this 
complex binds the serine-threonine kinase of mTORC1 
and inhibits signaling downstream. Everolimus has 
been extensively tested for several kinds of tumor types, 
and showed some significant and durable responses. In 
renal cell carcinoma, everolimus provided a significant 
benefit to patients with metastatic renal cell carcinoma 
after failure of treatment with sorafenib or sunitinib [2]. 
Adding everolimus to exemestane significantly improved 
median progression-free survival (PFS) compared with 
exemestane alone in the treatment of estrogen receptor-
positive, HER2-negative advanced breast cancer patients 
[3]. In addition, everolimus provided a significant 
reduction in volume and seizure frequency in patients 
with subependymal giant cell astrocytoma associated with 
tuberous sclerosis, and prolonged survival in pancreatic 
neuroendocrine tumor [4, 5]. 
However, there has not been a validated biomarker 
for predicting response to everolimus, yet. Previous 
studies used candidate gene approach for searching 
mutations and revealed that PI3K/AKT/mTOR pathway 
had an important role in everolimus sensitivity [6-8]. 
Recently, whole genome sequencing identified a somatic 
mutation for everolimus sensitivity in bladder cancer [9]. 
In this study, mutation of tuberous sclerosis 1 (TSC1) 
was suggested as a biomarker for everolimus response in 
bladder cancer. Similarly, one anaplastic thyroid cancer 
patient who showed sensitivity to everolimus, revealed a 
nonsense mutation in TSC2, a negative regulator of mTOR 
[10]. A recent study by Yoon et al. reported that pS6Ser240/4 
expression may be a predictive biomarker for everolimus 
sensitivity in gastric cancer patients [11]. Likewise, we 
recently discovered one patient who showed exceptional 
response to everolimus. 
We hypothesized that there are driver genetic events, 
which are clinically actionable and targetable, that occur 
commonly across different tumor types. In this study, 
we aim to perform next-generation sequencing (NGS) in 
patients with different tumor types to explore common 
genetic aberrations that confer sensitivity to everolimus. 
We recruited patients who were treated with single-agent 
everolimus, and sought to find universal biomarkers 
regardless of tumor types and histologic subtypes.
RESULTS
Everolimus leading to response in a patient with 
primary ductal adenocarcinoma of the lacrimal 
gland
Our index patient was a 51-year-old male who 
diagnosed with primary ductal adenocarcinoma of 
the lacrimal gland in the left. (Figure 1). The patient 
received multiple lines of chemotherapy, but patient 
showed aggravation of primary tumor and progression to 
bone metastasis. His tumor tissue was sent for targeted 
next-generation sequencing at Foundation Medicine 
profiling of 236 cancer-related genes and 47 introns of 
19 genes involved in rearrangement. The assay reported 
TP53 (Q38fs) mutation and NF1 (D1644A) mutation 
(Supplementary Figure S2A-B). While there were no 
approved therapies or clinical trials to address for TP53 
mutation and NF1 mutation at that time, a therapeutic 
attempt using everolimus 10mg once per day was 
initiated in October 2013 on the basis of data published 
by McGillicuddy et al, supporting the sensitivity of 
everolimus in loss-of-function mutation in the NF1 
tumor suppressor gene [12]. The patient was seen again 
1 month after, and we noticed decreased exophthalmus 
and reduced skin thickening around his left eyelid. In 
terms of subjective symptoms, he reported improved pain 
of his bone metastasis lesions in right humerus head and 
left shoulder. The PET-CT taken after 1 month showed 
a partial response as per PET response criteria [13], 
showing more than 25% reduction of SUVmax compared 
to baseline. He was maintained on everolimus and the CT 
scan taken after 2 months of therapy showed shrinkage 
of the measurable tumor lesions (26.5mm to 17.6mm, 
33.5% reduction). His tumor showed further decrease 
in SUVmax in the PET-CT scan taken after 4 months of 
therapy (Supplementary Figure 3). The partial response 
was maintained for 8 months. 
Patients’ characteristics
We collected a total of thirty-nine patients with five 
different tumor types (13 with gastric cancer, 15 with renal 
cell carcinoma, 2 with thyroid cancer, 2 with head and 
neck cancer, and 7 with sarcoma) were analyzed by NGS. 
As shown in Table 1, the median age of all patients was 57, 
and there were 24 (61.5%) males and 15 (38.5%) females. 
There were 22 (56.4%) patients with clinical benefit and 
17 (43.6%) patients without clinical benefit. Patients with 
clinical benefit included 9 patients with partial response 
(PR) and 13 patients with durable stable disease (SD), 
with 10 patients showing SD ≥ 6 months. All patients 
without clinical benefit showed progressive disease (PD) 
as their best response with no tumor shrinkage at all. The 
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median progression-free survival was 13.0 months (95% 
CI, 6.3-19.7) for patients with clinical benefit and 1.7 
months (95% CI, 1.54-1.85) for patients without clinical 
benefit. As of data cutoff, two patients were still under 
ongoing everolimus treatment (Supplementary Table 3, 4). 
Overall genetic alterations
To identify possible genetic mechanisms of 
sensitivity to everolimus, we performed targeted 
sequencing of the pre-treatment tumor and paired germline 
DNA. Tumors were sequenced to a median coverage of 
552x. Cancer genomes were characterized by 219 somatic 
single-nucleotide variants (181 missense, 9 nonsense, 7 
splice-site) and 22 frameshift insertions/deletions, with a 
median of 2.1 mutations per Mb (0 to 12.4 mutations per 
Mb). Of these alterations, 13 mutations were previously 
reported in the Catalogue of Somatic Mutations in Cancer. 
Mutations were further analyzed for functional prediction 
of amino acid changes using two different prediction 
algorithms (Provean and SIFT) (Supplementary Table 
5). TP53 gene alterations were the most common among 
all genes and were found in 8 of 38 tumors (21.1%). 
Recurrently mutated genes such as PBRM1, MTOR, NF1, 
VHL, PD34DIP, and ARID1A were found in patients with 
clinical benefit, in the order of frequency. In contrast, 
recurrently mutated genes such as VHL, TP53, and 
ARID1A were found in patients with non-clinical benefit. 
(Supplementary Figure S4). Sanger sequencing for mTOR 
pathway genes (MTOR/TSC1/TSC2/PIK3CA/NF1/NF2/ 
PTEN/AKT1) confirmed variants that were found in CCP 
panel (supplementary Figure S5 & supplementary Table 
6). 
Pathways relevant to everolimus sensitivity
We examined the sequencing data for biologically 
plausible mechanisms of sensitivity to everolimus, and 
identified multiple mutations in the mTOR-pathway 
(Figure 2). 
Two PIK3CA mutations were detected in patients 
with clinical benefit. A mutation in the helical domain of 
PIK3CA (p.E542K), which is known to be constitutively 
activating and selectively sensitive to everolimus [14], 
was found in a renal cell carcinoma patient with the PFS 
of 23.9 months. In addition, a kinase domain mutation 
Figure 1: The primary tumor located in the lacrimal gland seen in orbit MRI A. axial view B. coronal view. C. Hematoxylin 
& eosin staining of the tumor.
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of PIK3CA (p.H1047R) was found in a head and neck 
cancer patient with partial response. Alterations in 
TSC1 gene were noted in three patients: a patient with 
anaplastic thyroid cancer who harbored a nonsense 
mutation in TSC1 (p.Trp103*) and a renal cell carcinoma 
patient with a TSC1 splicing variant (c.1029+1G>A). In 
addition, a malignant histiosarcoma patient had TSC1 
missense mutation (p.A307V) and showed significant 
tumor reduction (-24.3%). One TSC2 missense mutation 
(p.E588K) was found in a gastric cancer patient. Three 
MTOR missense mutations (N1421D, K1771R, I1973F) 
were found in patients with gastric cancer, angiosarcoma 
and renal cell carcinoma, respectively. All three mutations 
were located in FAT (FRAP, ATM, TRAP) domain of 
MTOR. 
Overall, genomic alterations which may activate 
mTOR signaling were identified in 10 of 22 (45%) 
patients with clinical benefit (Figure 3A). In particular, 
TSC1/TSC2/MTOR mutations were key components 
in determining everolimus sensitivity (Figure 3B). The 
incidence of these mutations were 31.8% (7/22) in patients 
with clinical benefit as compared with 0% in those with 
non-clinical benefit (P=0.012). The prevalence of these 
recurrently mutated genes and their correlation with 
clinical benefit strongly suggest that they confer sensitivity 
to everolimus. 
While TSC1/TSC2/MTOR alterations were 
exclusively found in patients with clinical benefit, we 
also searched for recurrently mutated genes that were 
exclusively identified in patients with non-clinical benefit. 
Mutations in chromatin remodeling gene (BAP1; n=2, 
12%) and receptor tyrosine kinase signaling (FGFR4; 
Table 1: Baseline characteristics of all patients (n=39)
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n=2, 12%) were noted, but not statistically significant.
DISCUSSION
Here, we described multiple activating mutations in 
the mTOR pathway found in patient tumors that showed 
exquisite sensitivity to everolimus. TSC1/TSC2/MTOR 
alterations were exclusively found in patients who showed 
extended clinical benefit, which suggest that they confer 
sensitivity to everolimus. NF1 mutation together with 
TP53 mutation presents an aggressive tumor behavior, but 
tumor growth is effectively inhibited by everolimus. 
In theory, dependency on the mTOR pathway 
may render enhanced sensitivity to mTOR inhibitors. 
Three different mutations (N1421D, K1771R, I1973F) 
in the FAT domain of MTOR have not been previously 
reported in the publicly available genomic database [15]. 
Previously, it has been proposed that FAT domain consist 
of TRD1, TRD2 and TRD3 domain and interacts to yield 
a configuration that exposes the catalytic domain [16, 17]. 
Especially, N1421D was located in TRD1 domain which is 
important for mTOR function and both Provean and SIFT 
predicted that our mutation was deleterious mutation. In 
addition, K1771R mutation is located in TRD3 which is 
interact with the C lobe on one side of the kinase domain. 
Mutation of I1973 amino acid was previously reported to 
be hyperactivating mutation which involved in restricting 
active site access and both Provean and SIFT reported that 
I1973F is deleterious mutation [17].
TSC1 and TSC2 are upstream key negative 
regulators of mTORC1. They form a heterotrimer, a 
GTPase-activating protein for Rheb (Ras homologue 
enriched in brain), a GTP-binding protein that activates 
mTORC1 by binding to it. As the loss of TSC1-TSC2 
function activates mTORC1 pathway, strong scientific 
rationale exists for the use of mTOR inhibitors in this 
setting. Sirolimus has shown promising effects in patients 
with inactivating mutations in TSC1, TSC2 and STK11 in 
hamartoma syndromes such as tuberous sclerosis complex 
and Peutz-Jeghers Syndrome [18-20]. Moreover, 2 out of 
3 patients with malignant perivascular epithelioid cell 
tumors who had clinical response to sirolimus showed 
Figure 2: Landscape genomic profile of patients is seen. Genomic alterations which may activate mTOR signaling were identified 
in 10 of 22 (45%) patients with clinical benefit. Recurrently mutated genes of FGFR4 and BAP1 were noted only in patients without clinical 
benefit (P = NS).
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TSC1/2 loss [21]. There was a recent report of renal cell 
carcinoma patients with extended benefit from mTOR 
inhibitor showed that TSC1 and TSC2 offer explanation 
for treatment response [22]. Similarly, we identified 1 
TSC1 splicing variant (renal cell carcinoma), 1 TSC1 
nonsense mutation (anaplastic thyroid cancer), 1 TSC1 
missense mutation (sarcoma) and 1 TSC2 missense 
mutation (angiosarcoma). Given that heterozygous loss 
of TSC1 is common in renal cell carcinoma (>30%) [23], 
TSC1 and TSC2 may be screened as predictive biomarkers 
of everolimus in renal cell carcinoma patients who 
progressed on VEGF-targeted therapy.
Loss-of-function mutations in the NF1 tumor 
suppressor gene affects mTOR pathway, leading to 
constitutive activation of mTOR. This activation depends 
on Ras and PI3 kinase, and is mediated by the inactivation 
of the TSC2-encoded protein tuberin by AKT [24]. In this 
way, NF1-deficient tumors alone may show exquisite 
sensitivity to mTOR inhibitors. In conjunction with our 
index patient with TP53 and NF1 mutation, it has been 
reported that NF1 heterozygosity cooperates with TP53 
mutation to promote tumorigenesis. Homozygous null 
NF1 mutations may occur, which mediate sensitivity 
to mTOR inhibitors [12]. Although rare in tumors such 
as gastric cancer, sarcoma, and renal cell carcinoma, 
recent finding that NF1 mutations are enriched (11%) in 
oncogene-negative subset of lung adenocarcinomas, and 
our finding suggests novel therapeutic opportunities for 
the subset of patients with NF1 mutations. 
Conceptually, activating mutations within 
the phosphoinositide 3-kinase, catalytic subunit α 
(PI3K-p110 α) encoded by the PIK3CA gene, lead to 
mTOR pathway activation [6, 25]. In this study, activating 
PIK3CA mutations in helical domain (p.E542K), and 
kinase domain (p.H1047R) were found in a renal cell 
carcinoma and a parotid gland choriocarcinoma patient, 
respectively. However, one patient with a PIK3CA 
mutation (p.H1047R) showed non-clinical benefit to 
everolimus, showing rapid increase of ascites within 1 
month of everolimus treatment. That activating PIK3CA 
mutation does not always lead to response was previously 
reported by Janku et al. where they described patients with 
H1047R PIK3CA mutation experienced a response rate of 
44% [26].
Our study has a few limitations. Although 
prespecified, the selected patients with clinical benefit in 
this study may only explain a portion of mechanisms of 
sensitivity. Other genetic or epigenetic alterations that are 
not covered in the CCP may be missed out even if they 
regulate sensitivity or resistance to everolimus. Because 
study was retrospective in nature, and the number of 
patients analyzed was relatively small, these data must be 
interpreted cautiously 
However, to the best of our knowledge, this is 
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the first report that identified histology-independent 
mechanisms of sensitivity to mTOR inhibitor in multiple 
tumor types. Regardless of histology, mTOR pathway-
activating mutations confer exceptional response to 
everolimus, and this provides the rationale for the 
development of so-called basket trials. The current study 
highlights the fact that mutational analyses of somatic 
variants could allow sub-classification of patients for 
optimal treatment, and provides a basis for a basket trial 
in the future. These efforts will eventually increase the 
likelihood of success of drug trials especially in patients 
with rare cancer types.
In conclusion, the genomic information derived 
from patients with exceptional clinical benefit may provide 
a basis for everolimus sensitivity. Overall, it seems that 
screening for TSC1/TSC2/MTOR mutations warrants 




We recruited tissue samples and matched blood 
samples among patients who participated in the clinical 
trials using everolimus and renal cell carcinoma patients 
treated with everolimus as a standard second line of 
therapy (Supplementary Table 1). Patients with extended 
clinical benefit and non-benefit were selected for this 
study. The criteria for extended clinical benefit were: 
1) complete response or 2) partial response for more 
than 6 months or 3) durable stable disease with PFS on 
everolimus ≥ 1.5 x PFS of prior treatment. The criteria for 
non-benefit were 1) no shrinkage in tumor diameter and 2) 
progressive disease as best response.
Clinical information including age, sex, treatment 
duration, best response to treatment, percent change in 
tumor size, previous treatment history and survival data 
were collected. The study protocol was approved by each 
center’s independent ethics committee or institutional 
review board and was conducted in accordance with the 
Declaration of Helsinki and Good Clinical Practice. All 
patients provided written informed consent for genomic 
testing used for this study. Specimens were evaluated by 
pathologists (H.K.K) to identify tumor-bearing areas for 
DNA extraction. 
Targeted sequencing 
Tumor genomic DNA was extracted from formalin-
fixed, paraffin-embedded (FFPE) tumor tissue blocks, 
unstained 10 um thick tissue sections. All samples were 
micro-dissected to ensure ≥70% tumor contents. Normal 
genomic DNA was extracted from either peripheral blood 
mononuclear cells or histologically confirmed normal 
tissue. Library preparation for each sample was performed 
Figure 3: A. Genetic alterations identified in patients with clinical benefit B. Best overall response of patients with clinical benefit, with 
negative values indicating tumor shrinkage and the vertical axis indicating treatment duration in months. Nonsynonymous mutations for 
each patient are marked accordingly.
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using Ion AmpliSeqTM Comprehensive Cancer Panel 
(CCP, Life Technology) following the manufacturer’s 
instructions. The pooled capture library was quantified 
by Qubit (Invitrogen) and Tape station (Agilent) and 
sequenced by Ion ProtonTM System. Two patients 
(anaplastic thyroid cancer and renal cell carcinoma) were 
sequenced by Sanger sequencing using primers for all 
coding region of TSC1. 
Analysis of molecular aberrations
Ion AmpliSeq™ Comprehensive Cancer 
Panel (CCP, Life Technologies) was used for cancer 
specific target sequencing, targeting 409 genes with 
~16,000 amplicons. Sequencing was processed by Ion 
PGMTM system and sequencing data was analyzed by 
PGMTM built in TSS (Torrent Suite Software) 4.0.2 version 
(Supplementary Fig S1). Variants acquired from the CCP 
panel were filtered by germline variants acquired from 
our patients and 1000 genome data. Mutations with less 
than 50x depth and less than 10% variant frequency were 
filtered out [27]. Quality score, a parameter of variant 
call format using phred scale, was used to filter out the 
variants and Q30 was used for cut-off value [27]. Then, 
variants were annotated using ANNOVAR [28] and non-
coding region and synonymous variants were filtered out. 
Remaining variants were assessed using the Integrative 
Genomics Viewer (IGV) [29] and loci were further 
analyzed for functional prediction of amino acid changes 
using two different prediction algorithms (Provean 
and SIFT) [30, 31]. Mutations in MTOR, TSC1, TSC2, 
PIK3CA, NF1, NF2, PTEN, AKT1 were validated by 
Sanger sequencing or pyrosequencing. Sanger sequencing 
and pyrosequencing primers listed in the supplementary 
table 2. 
Statistical analyses
Tumor response was evaluated using the RECIST 
v1.1 [32] and progression-free survival (PFS) was 
defined as the time from the start of everolimus to 
disease progression or death from any cause. Statistical 
significance of preferential association of somatic 
variations with specific clusters was assessed with chi-
square test or Fisher’s exact test. All statistical analyses 
were performed using SPSS 20.0 (SPSS, Chicago, IL, 
USA).
Abbreviations
PFS: progression-free survival; NGS: next-
generation sequencing; FFPE: formalin-fixed, paraffin-
embedded; CCP: Comprehensive Cancer Panel; IGV: 
Integrative Genomics Viewer; RECIST: Response 
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SD: stable disease; PD: progressive disease
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